Poster #2 – Characterization of acquired resistant models to therapies targeting the PD-1 / PD-L1 axis demonstrates model-dependant mechanisms
Poster #3 – DIACCURATE : DIACC3010, optimized inhibitor of S6 kinase, combined with endocrine therapy, has potent antitumor activity in treatment-resistant ER+ HER2 – metastatic breast cancer
Poster #4 – BRENUS PHARMA : 1179 efficacity study of STC-1010 antitumor vaccine associated with standard chemotherapies on MC38 syngeneic colon cancer tumor model
